## APC/Cy7 anti-mouse CD45.1

**Catalog # / Size:**  $1153575 / 25 \mu g$ 

 $1153580 / 100 \mu g$ 

Clone: A20

**Isotype:** Mouse IgG2a, κ

Immunogen: SJL mouse thymocytes and splenocytes

Reactivity: Mouse

**Preparation:** The antibody was purified by affinity


chromatography, and conjugated with APC/Cy7 under optimal conditions. The solution is free of unconjugated APC/Cy7

and unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2,

containing 0.09% sodium azide.

Concentration: 0.2



SJL mouse splenocytes were stained with CD45.1 (clone A20) APC/Cy7 (filled histogram) or mouse IgG2a APC/Cy7 isotype control (open histogram).

## **Applications:**

**Applications:** Flow Cytometry

Recommended

Usage:

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of

this reagent is ≤1.0 microg per million cells in 100 microL volume. It is recommended that the reagent be titrated for optimal performance for each

application.

Application Notes:

The A20 antibody does not react with leukocytes or mouse cells expressing the CD45.2 alloantigen. Additional reported applications (for relevant formats of this clone) include: immunoprecipitation3, *in vitro* blocking of B cell responses<sup>1,2</sup>, immunohistochemical staining of frozen sections: OCT embedded<sup>7</sup> and acetone-fixed<sup>4-6</sup> (direct immunofluorescence detection with fluorochrome conjugated A20 was used in (5) and (6)), and immunofluorescence microscopy<sup>9</sup>.

Application References:

1. Yakura H, et al. 1983. J. Exp. Med. 157:1077. (Block)

2. Yakura H, et al. 1986. J. Immunol. 136:2729. (Block)

3. Shen FW, et al. 1986. Immunogenetics 24:146. (IP)

4. Suzuki K, et al. 2000. Immunity 13:691. (IHC)

5. Werner N, et al. 2002. Arterioscler. Thromb. Vasc. Biol. 22:1567. (IHC)

6. Lessner SM, et al. 2002. Am. J. Pathol. 160:2145. (FC, IHC)

7. Chen CC, et al. 2005. P. Natl. Acad. Sci. USA 102:11408 (IHC)

8. Pascal V, et al. 2007. J. Immunol. 179:1751. (FC)

9. Mende I, et al. 2006. Blood 107:1383. (IF, IHC, FC)

10. Phan TG, et al. 2007. Nature Immunol. 8:992. (FC)

11. Wither DR, et al. 2009. J. Immunol. 183:5079. PubMed

12. Pascal V, et al. 2007. J. Immunol. 179:1751. PubMed

13. Lee SW, et al. 2009. J. Immunol. 182:6753. PubMed

14. Takada K, et al. 2009. J. Exp Med. 206:2253. PubMed

15. Beamer CA, et al. 2007. Am. J. Respir. Cell. Mol. Biol. 37:729. (FC) PubMed

16. Li LX, et al. 2010. J. Immunol. 184:1728. PubMed

17. Hosoi A, et al. 2008. Cancer Res. 68:3941. (FC) PubMed

18. Kenna TJ, et al. 2008. Blood 111:2091. PubMed

- 19. Kohlmeier JE, et al. 2008. Immunity. 29:101. (FC) PubMed
- 20. Burgess MR, et al. 2014. Blood. 124:3947. PubMed

## **Description:**

CD45.1 is an alloantigen of CD45, expressed by Ly5.1 bearing mouse strains (e.g., RIII, SJL/J, STS/A, DA). CD45, a member of the protein tyrosine phosphatase (PTP) family, is a 180-240 kD glycoprotein expressed on all hematopoietic cells except mature erythrocytes and platelets. There are multiple isoforms in mice that play key roles in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation states of the cell as well as specific cell types. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.

## Antigen References:

- 1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
- 2. Trowbridge IS, et al. 1993. Annu. Rev. Immunol. 12:85.
- 3. Kishihara K, et al. 1993. Cell 74:143.
- 4. Pulido R, <